Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease

Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease

PURPOSE The risk of immune checkpoint inhibitor therapy–related GI adverse events in patients with cancer and inflammatory bowel disease (IBD) has not been well described. We characterized GI adverse events in patients with underlying IBD who received immune checkpoint inhibitors. PATIENTS AND METHO...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Hamzah Abu‐Sbeih, David M. Faleck, Biagio Ricciuti, Robin B. Mendelsohn, Abdul Rafeh Naqash, Justine V. Cohen, Maclean C. Sellers, Aanika Balaji, Guy Ben‐Betzalel, Hajir Ibraheim, Jiajia Zhang, Mark M. Awad, Giulia C. Leonardi, Douglas B. Johnson, David J. Pinato, Dwight H. Owen, Sarah A. Weiss, Giuseppe Lamberti, Mark P. Lythgoe, Lisa Manuzzi, Christina A. Arnold, Wei Qiao, Jarushka Naidoo, Gal Markel, Nick Powell, Sai‐Ching J. Yeung, Elad Sharon, Michael Dougan, Yinghong Wang
Médium: Artigo
Jazyk:angličtina
Vydáno: 2019
On-line přístup:https://doi.org/10.1200/jco.19.01674
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Internet

https://doi.org/10.1200/jco.19.01674

Podobné jednotky